<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pkgmetadata SYSTEM "http://www.gentoo.org/dtd/metadata.dtd">
<pkgmetadata>
	<longdescription>
		Utility-Based Optimal Phase II/III Drug Development Planning //
		Plan optimal sample size allocation and go/no-go decision rules
		for phase II/III drug development programs with time-to-event,
		binary or normally distributed endpoints when assuming fixed
		treatment effects or a prior distribution for the treatment
		effect, using methods from Kirchner et al. (2016)
		doi:10.1002/sim.6624 and Preussler (2020). Optimal is in the
		sense of maximal expected utility, where the utility is a
		function taking into account the expected cost and benefit of
		the program. It is possible to extend to more complex settings
		with bias correction (Preussler S et al. (2020)
		doi:10.1186/s12874-020-01093-w),  multiple phase III trials
		(Preussler et al. (2019) doi:10.1002/bimj.201700241), multi-arm
		trials (Preussler et al. (2019)
		doi:10.1080/19466315.2019.1702092), and multiple endpoints
		(Kieser et al. (2018) doi:10.1002/pst.1861).
	</longdescription>
</pkgmetadata>
